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ORIGINAL ARTICLE
Triggers and Treatment of Anaphylaxis
An Analysis of 4000 Cases From Germany, Austria and Switzerland
Margitta Worm*, Oliver Eckermann*, Sabine Dölle, Werner Aberer, Kirsten Beyer,  
Thomas Hawranek, Stephanie Hompes, Alice Koehli, Vera Mahler, Katja Nemat, Bodo Niggemann, 
Claudia Pföhler, Uta Rabe, Angelika Reissig, Ernst Rietschel, Kathrin Scherer, Regina Treudler,  
Franziska Ruëff
SUMMARY
Background: Anaphylaxis is the most severe manifestation 
of a mast cell–dependent immediate reaction and may be 
fatal. According to data from the Berlin region, its inci-
dence is 2–3 cases per 100 000 persons per year.
Methods: We evaluated data from the anaphylaxis registry 
of the German-speaking countries for 2006–2013 and data 
from the protocols of the ADAC air rescue service for 
2010–2011 to study the triggers, clinical manifestations, 
and treatment of anaphylaxis.
Results: The registry contained data on 4141 patients, and 
the ADAC air rescue protocols concerned 1123 patients. In 
the registry, the most common triggers for anaphylaxis 
were insect venom (n = 2074; 50.1%), foods (n = 1039; 
25.1%), and drugs (n = 627; 15.1%). Within these groups, 
the most common triggers  were wasp (n = 1460) and bee 
stings (n = 412), legumes (n = 241), animal proteins (n = 
225), and analgesic drugs (n = 277). Food anaphylaxis 
was most frequently induced by peanuts, cow milk, and 
hen's egg in children and by wheat and shellfish in adults. 
An analysis of the medical emergency cases revealed that 
epinephrine was given for grade 3 or 4 anaphylaxis to 
14.5% and 43.9% (respectively) of the patients in the 
 anaphylaxis registry and to 19% and 78% of the patients 
in the air rescue protocols. 
Conclusion: Wasp and bee venom, legumes, animal 
 proteins, and analgesic drugs were the commonest 
triggers  of anaphylaxis. Their relative frequency was age-
dependent. Epinephrine was given too rarely, as it is 
 recommended in the guidelines for all cases of grade 2 
and above.
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A naphylaxis is defined as an acute systemic reac-tion with the symptoms of an immediate allergic 
reaction that can affect the entire organism and is po-
tentially life-threatening (1–3). Anaphylaxis can be 
fatal or lead to permanent damage (3). Pathophysio -
logically, anaphylactic reactions—especially those trig-
gered by foods or insect venom—are predominantly 
IgE-mediated, but in rare cases direct activation of the 
mast cells can be the cause.
At present no uniform worldwide definition of an-
aphylaxis exists. A mechanistic approach uses the term 
“anaphylaxis” for systemic generalized reactions of all 
degrees of severity (4). The definition most often used 
today describes anaphylaxis as a severe generalized 
reaction with symptoms in various organ systems (skin 
and mucosa, respiratory tract, cardiovascular system, 
gastrointestinal tract) (5). The differential diagnosis of 
anaphylaxis includes a large number of possible condi-
tions (Box).
Epidemiology
Although data exist worldwide on the epidemiology of 
anaphylaxis, the triggers and their prevalences vary 
from region to region and depending on the patient 
group(s) studied (6, 7). One central problem is that the 
ICD-10 coding system does not make provision for 
coding the various forms of anaphylactic reaction or for 
anaphylactic shock with a single code, so studies 
 working on the basis of ICD-10 diagnoses have to take 
account of several code numbers in order to collect data 
on anaphylaxis in an appropriate way. 
Data from the US on the epidemiology of anaphy -
laxis suggest an incidence of up to 40 to 50 people per 
100 000 population per year (8), whereas the figures for 
England are somewhat lower at 6 to 8 cases per 
100 000 population (9).
A recently published study by our working group in 
collaboration with Berlin emergency physicians 
showed an anaphylaxis incidence of 2 to 3 people per 
100 000 population (10). Although the data vary ac-
cording to where they were collected, who the target 
group was, and the selection criteria for the group, 
nevertheless, overall they show that anaphylaxis, the 
most severe manifestation of an allergic reaction, is a 
rare event.
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Studies from the USA and Australia suggest that the 
number of patients experiencing anaphylaxis has in-
creased during the past few decades (8, 11). This relates 
most of all to severe allergic reactions triggered by food 
or drugs (8).
Treatment of anaphylaxis
According to the current guidelines for the acute treat-
ment of anaphylaxis, the first-line treatment for patients 
with severe allergic reactions who show respiratory 
and/or cardiovascular symptoms is intramuscular 
 adminstration of epinephrine (12)—although the evi-
dence for this is poor because of a lack of controlled 
studies (13).
Measures such as appropriate positioning of the 
 patient and the giving of fluids and oxygen are further 
basics of treatment. Additional drugs that should be 
given in the acute situation are H1-receptor–blocking 
antihistamines and corticosteroids, although here too 
controlled studies on the effectiveness of these drugs in 
treating anaphylaxis are lacking (9). In patients with 
symptoms of asthma, additional treatment with 
 inhalational β2-sympathomimetics is recommended. A 
summary of currently recommended therapeutic 
measures for anaphylaxis is given in Table 1.
Aim of the study
The aim of the present study was to identify the triggers 
of anaphylaxis from data in the anaphylaxis registry of 
the German speaking countries, and to present them 
and their relative frequencies in relation to patient age. 
To gain a picture of the care situation for anaphylaxis 
patients in the German-speaking countries, data from 
the anaphylaxis registry relating to care are presented in 
comparison with primary data obtained from emergen-
cy physicians (from the Berlin area as a sample, and 
from the ADAC air rescue service for the whole of 
 Germany).
Methods
The study was carried out as a retrospective evaluation 
of data from the anaphylaxis registry (this records data 
about patients with severe allergic symptoms; that is, 
skin or mucosal symptoms and respiratory and/or car-
diovascular symptoms in relation to triggers, symp-
toms, diagnostic procedures, concomitant diseases, and 
care) from 2006 to 2013, and from the documented 
callouts of the ADAC air rescue service from 2010 to 
2011.
The data from the survey of Berlin area emergency 
physicians have been published previously; in the 
 present analysis they are reused only for purposes of 
comparison for the 2010 to 2011 time period (10). A 
 detailed description of the methods and statistical 
evaluation is provided in eBox 1.
Results
The results presented here include all cases reported to 
the registry from 1 January 2006 to 31 March 2013. 
A total of 4141 cases from Germany, Austria, and 
 Switzerland were included (inclusion criteria: adequate 
severity of reaction no more than 12 months in the 
past). Of these, 2173 patients were female and 1968 
were male. In the overall group, 3168 were adults 
(1840 female, 1328 male) and 973 were children (333 
female and 640 male). Classification of the patients on 
the basis of their reported symptoms into Ring and 
Messmer severity grades (4) (Table 2) shows that in 
 accordance with the inclusion criteria >85% of the 
reactions were equivalent to severity grade II or III. 
Grade IV reactions were rarely reported (n = 107): 
among adults, the percentage was 3.1% and among 
children it was 0.9% of cases (Figure 1).
Trigger profile
Among children (0 to 17 years), the most frequently re-
ported triggers of severe allergic reactions were foods 
(Figure 2). Among adults (>18 years), insect venom 
was the most often reported trigger of severe allergic 
reactions. In terms of detailed trigger profile, further 
analyses showed that food allergens such as hen's egg, 
cow’s milk, tree nut and peanut (14) were predomi-
nantly reported in children (Figure 3). In adults, foods 
ranked third as triggers of severe allergic reactions 
(Figure 2), when the data from the anaphylaxis registry 
were included. In this group, the most frequently 
 reported food allergens were wheat, celery, soy, and 
shellfish (Figure 3). Table 3a shows individual foods as 
triggers of severe allergic reactions in the overall 
 patient group. 
Drugs also triggered severe allergic reactions, es-
pecially nonsteroidal anti-inflammatory substances 
(Table 3b). Triggers in this group include diclofenac, 
acetylsalicylic acid, and ibuprofen (Table 3c). Another 
major drug group that triggered anaphylactic reactions 
was antibiotics, particularly penicillins and cephalospo-
rins. Of the insect venoms, the most frequently reported 
trigger was wasp venom (1460 = 70.4%), less fre-
quently bee venom (419 = 19.9%) or others (Table 3d).
Emergency care
The emergency care data obtained from the anaphy -
laxis registry were generated from patient data; this did 
not always include details of emergency care protocols. 
For this reason, we compared the data from the anaphy-
laxis registry to primary data from the Berlin emergen-
cy physician service and the ADAC nationwide air 
 rescue service.
The results show that the majority of patients with 
anaphylactic reactions primarily received antihis -
tamines and corticosteroids, and a smaller percentage 
 received epinephrine, as part of their emergency treat-
ment (Figure 4). It should be noted that the data from 
the anaphylaxis registry and the Berlin emergency 
physicians are results that include Ring and Messmer 
(4) severity grades II to IV. The air rescue data were 
evaluated in a retrospective manner that also included 
severity grade I. The frequency with which epinephrine 
was used as a first-line drug from severity grade II on-
wards in accordance with national and international 
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guidelines varied among the severity grades. For sever-
ity grade III, the usage rate was 14.5% for the data from 
the anaphylaxis registry, 25% for the Berlin emergency 
physicians, and 19% for the air rescue service. For 
 severity grade IV, the usage rates were 43.9% for the 
anaphylaxis registry data, 100% for the Berlin emer -
gency physicians, and 78% for the air rescue service.
Discussion
With the aid of the anaphylaxis registry, we have for the 
first time succeeded in collecting clinical epidemiologi-
cal data on patients with anaphylaxis in the German-
speaking countries using a standardized form of data 
collection. Data on the triggers of anaphylaxis show 
that their relative frequency depends on patient age. 
The leading triggers are foods, insect venoms, and 
medical drugs. Comparable data are available from 
other studies in Europe, e.g., France and Spain (15, 16).
In the literature, milk and hen's egg are described as 
frequent triggers of anaphylaxis in young children (14), 
while in school-age children peanuts and tree nuts 
(hazel nut, walnut, cashew, Brazil nut, macadamia) fre-
quently occur as triggers of a food allergy, not just in 
Europe, but also in the US (17). This also agrees with 
the results of the present study, in which these food 
 allergens were predominantly reported as triggers of 
 severe allergic reactions in children. 
Food allergens as triggers of anaphylaxis are also de-
termined by the eating habits of a given population; for 
example, shellfish are frequent triggers of anaphylactic 
BOX
Differential diagnoses of anaphylaxis
● Cardiovascular events
– Vasovagal syncope
– Other forms of shock  
(e.g., hemorrhagic, cardiogenic)
– Cardiac arrhythmias
– Hypertensive crisis
– Pulmonary embolism
– Capillary leak syndrome
● Endocrinological/metabolic events
– Carcinoid syndrome
– Pheochromocytoma
– Thyrotoxic crisis
– Hypoglycemia
● Psychogenic events
– Hyperventilation, especially with globus hystericus 
 attacks
– Multiple chemical sensitivity (MCS)
– Münchhausen syndrome (anaphylaxis as artifact)
● Cerebral events
– Epilepsy
– Stroke
– Coma (without anaphylaxis), e.g., metabolic, 
 traumatic
● Airway events
– Vocal cord dysfunction, psychogenic respiratory 
 distress
– Tracheal/bronchial obstruction (e.g., foreign body, 
tumor)
– Asthma (without anaphylaxis)
● Pharmacological/toxic events
– Due to drugs (e.g., local anesthetic i.v.)
– Due to alcohol and administration of substances that 
cause a disulfiram-like reaction (e.g., griseofulvin, 
sulfonyl ureas, certain fungal toxins)
(Modified from Ring et al. [12])
TABLE 1
Recommendations for emergency drug treatment in 
 patients with anaphylaxis (adapted from Ring et al. [12])
Note: An emergency kit for immediate treatment should include written instruc -
tions for using the medication (e.g., anaphylaxis card and/or anaphylaxis 
 emergency plan)
Drug substance
Epinephrine
Antihistamine
Corticosteroid
Optional β-mimetic, 
e.g., salbutamol
Application route and dosage
Autoinjector for intramuscular 
 administration, weight-adjusted:  
 >10 kg 150 µg epinephrine  
 >30 kg 300 µg epinephrine
Depending on patient age and prefer -
ence, oral as a fluid or as (soluble) 
 tablets; the permitted daily dose of any 
antihistamine can be recommended as 
a single dose. For dimetindene drops, 
similarly, a weight-adjusted dosage of 
the i.v. formulation can be recom -
mended as dose to be taken orally
Depending on patient age and prefer -
ence, rectal or oral (as fluid or tablets) 
50–100 mg prednisolone-equivalent 
dose
In patients with known bronchial 
 asthma: β2-sympathomimetic; in 
 patients with expected obstruction of 
the airways: inhalational epinephrine 
preparation with spray head for drug 
vial (ask the pharmacist)
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reactions in Asia (18). Among adults in the German-
speaking countries, the predominant trigger of anaphy-
laxis is insect venom. Here, the necessity of an appro-
priate allergological diagnostic work-up and initiation 
of therapy must be particularly emphasized, as specific 
immune therapy offers a possible causal treatment to 
build up strong protection against the case of another 
sting (19).
The data on medical drugs as triggers show high 
numbers of reactions, especially for painkillers and 
antibiotics. It should be taken into account that these 
drugs are in very widespread use. To what extent 
 additional factors such as the presence of an active 
infection are significant for the triggering of an 
 anaphylactic reaction needs to be investigated in 
 future studies.
TABLE 2
Severity scale for classification of anaphylactic reactions 
(Modified from Ring and Messmer 1977 [4]); flushing = sudden erythema 
Grade
I
II
III
IV
Skin and subjective 
 generalized symptoms
Itching
Flushing
Urticaria
Angioedema
Itching
Flushing
Urticaria
Angioedema
Itching
Flushing
Urticaria
Angioedema
Itching
Flushing
Urticaria
Angioedema
Abdomen
–
Nausea
Cramps
Vomiting
Vomiting
Diarrhea
Vomiting
Diarrhea
Respiratory tract
–
Rhinorrhea
Hoarseness
Dyspnea
Laryngeal edema
Bronchospasm
Cyanosis
Respiratory arrest
Cardiovascular
–
Tachycardia (rise >20/min) 
Hypotension (fall >20 mm Hg systolic) 
Arrhythmia
Shock
Cardiovascular arrest
FIGURE 1Distribution of 
severity grades 
(Ring and Messmer 
[4]) of cases 
 reported to the 
 anaphylaxis registry 
(n = 4141) (1 Janu-
ary 2006 to 31 
March 2013); 95% 
CI, 95% confidence 
interval. Respiratory 
and/or cardiovascu-
lar symptoms are 
inclusion criteria for 
the registry, and 
therefore grade I is 
under-represented 
in this population
Percent (95% CI)
60
50
40
30
20
10
 0
Grade I Grade II Grade III Grade IV
Total: n = 4141
Children/adolescents  
(0 to 17 years): n = 937
Adults  
(>18 years): n = 3168
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kit consisting of an epinephrine autoinjector, an 
 antihistamine, and cortico steroids, together with 
 sufficient training in how to use them in an emergency 
situation (12). 
For the insect venoms (bee and wasp), suitable skin 
test solutions and specific IgE tests are available, 
whereas for drugs (skin and IgE test) and foods (mainly 
skin test), only limited diagnostic procedures are avail-
able. Further diagnostic procedures after an anaphy -
lactic reaction should always be carried out by appro-
priately qualified medical specialists. 
Even if foods or drugs triggered the anaphylaxis, 
 according to the guidelines for the management of 
 anaphylaxis, further allergological diagnostic tests 
should be carried out in all patients—including skin 
(preferably prick test), blood (specific serum IgE) 
and provocation tests (as appropriate)—to enable 
 appropriate counseling (12). As up to a third of 
 patients can have repeated severe allergic reactions 
(20), in addition to an allergy card recording the 
time, trigger, and symptoms of the reaction that has 
occurred, patients should be issued with an emergency 
Relative percent -
ages of the most 
frequent trigger 
groups related to 
the age of the pa-
tients reported in 
the anaphylaxis 
registry (n = 4141) 
(1 January 2006 to 
31 March 2013); 
95% CI, 95% confi-
dence interval
Percent (95% CI) 
70
60
50
40
30
20
10
Insect venom Foods Drugs Other
 0
Unknown
Adults: (>8 years):  
n = 3168 (100%) 
Children/adolescents 
(0–17 years): n = 937 
(100%)
FIGURE 2
The ten most common food allergens as triggers in various age groups (n = 665, children and adolescents 0–17 years, adults >18 years) among cases reported 
in the anaphylaxis registry (1 January 2006 to 31 March 2013); 95% CI, 95% confidence interval
Number (95% CI)
200
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 60
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FIGURE 3
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Data on the emergency care of patients with severe 
allergic reactions show a discrepancy between the treat-
ment recommendations given in current guidelines 
(epinephrine administration is recommended as a first 
line treatment from grade II upward) and the drugs 
 actually given to patients (12, 21). This discrepancy is 
particularly obvious when the data are analyzed inde-
pendently of severity grade.
In the overall group of patients, 12.3% from the 
 anaphylaxis registry, 8.6% of those in the air rescue 
data, and 21.6% of those in the Berlin emergency 
 physician records were given epinephrine. Among 
those with grade IV severity, however, the rate of epi-
nephrine administration rises to 43.9% (anaphylaxis 
registry), 78% (air rescue service) and 100% (Berlin 
emergency physicians). Until now, seven deaths have 
been recorded in the anaphylaxis registry (six in Ger-
many and one in Austria; the triggers were food in three 
cases, wasp venom in three cases, and in one case a 
medical drug). The statistics show a high survival rate; 
however, it needs to be kept in mind that the data 
 reported to the anaphylaxis registry is generally ob-
tained from patients who actively attend an allergy 
center for diagnosis and treatment. 
The evidence that epinephrine administration has a 
positive influence on the survival of anaphylaxis 
 patients is derived from earlier studies (13, 22, 23). On 
the basis of these study results, epinephrine is recom-
mended as the drug of choice in the guidelines for the 
acute treatment of severe allergic reactions (12), even 
though there are no prospective controlled studies of 
TABLE 3a
Foods triggering anaphylaxis  
(n = 1039, total study group = 4141)
*95% confidence interval calculated using the Clopper-Pearson interval
Food
Legumes
Foods of animal origin
Nuts
Cereals
Fruit
Vegetables
Herbs/seeds/kernels
Food additives
Other
n
241
225
199
101
65
63
55
13
77
%
23.2
21.7
19.1
9.6
6.3
6.1
5.3
1.3
7.4
95% CI*
20.7–25.9
19.2–24.3
16.8–21.7
8.0–11.7
4.9–7.9
4.7–7.7
4.0–6.8
0.7–2.1
5.9–9.2
TABLE 3b
Drugs triggering anaphylaxis 
(n = 627, total study group = 4141)
*95% confidence interval calculated using the Clopper-Pearson interval
Drug group
Painkillers
Antibiotics
Local anesthetics
X-ray contrast agents
Proton pump inhibitors
Muscle relaxants
Opiates
Corticosteroids
Cardiovascular drugs (ACE 
inhibitors, β-blockers)
Biologics
Volume replacement fluids
Chemotherapeutics
Vaccines
General anesthetics
Other drugs
n
277
135
60
26
20
19
15
8
7
5
5
4
3
1
42
%
44.2
21.5
9.6
4.1
3.2
3.0
2.4
1.3
1.1
0.8
0.8
0.6
0.5
0.2
6.7
95% CI*
40.2–48.2
18.4–25.0
7.4–12.1
2.7–6.0
2.0–4.9
1.8–4.7
1.3–3.9
0.6–2.5
0.5–2.3
0.3–1.9
0.3–1.9
0.2–1.6
0.1–1.4
0.0–0.9
4.9–8.9
TABLE 3c
Painkillers triggering anaphylaxis 
(n = 277, total study group = 4141)
*95% confidence interval calculated using the Clopper-Pearson interval
Painkiller
Diclofenac
Acetylsalicylic acid
Ibuprofen
Metamizole
Mefenaminic acid
Paracetamol
Propyphenazone
Painkiller  
(not further specified)
n
84
48
44
36
9
6
2
48
%
30.3
17.3
15.9
13.0
3.3
2.2
0.7
17.3
95% CI*
25.0–36.1
13.1–22.3
11.8–20.7
9.3–17.5
1.5–6.1
0.8–4.7
0.1–2.6
13.1–22.3
TABLE 3d
Insect venoms triggering anaphylaxis 
(n = 2074, total study group = 4141)
*95% confidence interval calculated using the Clopper-Pearson interval
Insect venom
Wasp
Bee
Hornet
Bumble-bee
Horsefly
Mosquito, midge
Insect (nonspecific)
n
1460
412
93
5
4
4
96
%
70.4
19.9
4.5
0.2
0.2
0.2
4.6
95% CI*
68.4–72.4
18.2–21.6
3.6–5.5
0.1–0.6
0.1–0.5
0.1–0.5
3.8–5.6
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the efficacy and tolerability of epinephrine in the treat-
ment of anaphylaxis. It has been shown that patients 
who had received two doses of epinephrine before they 
reached the emergency room were less often hospital-
ized than patients who received the second or both 
doses in the emergency room. However, the case 
numbers in these cohorts were small (n = 58). Like-
wise, it was observed that persons who died as a result 
of an anaphylactic reaction had either received no or 
delayed epinephrine (23).
Various factors may explain the reluctance to use 
epinephrine in acute therapy, especially in patients with 
grade II and III reactions. The therapeutic window for 
epinephrine is narrow, and in the past cardiovascular 
complications were reported in patients with pre-exist-
ing cardiovascular conditions (24, 25). An overdose can 
also be fatal (23). On the other hand, in children and 
young adults the risk of unwanted cardiovascular ef-
fects such as tachyarrhythmia can be regarded as low.
Epinephrine was given by the Berlin emergency 
physicians more often than by the air rescue emergency 
physicians; in stage IV patients the Berlin physicians 
gave it in 100% of cases. A significant factor here might 
be that the project was presented to the Berlin emergen-
cy physicians before the data collection started, in a 
format similar to a training course, and therefore posi-
tive effects may have occurred in terms of the recogni-
tion of an anaphylactic reaction and the consequent use 
of epinephrine. Future activities will aim to train phy -
sicians and patients in the emergency care of anaphy -
laxis in a standardized way. Physicians in other medical 
specialties, such as general practitioners, radiologists, 
and oncologists, and other medical personnel (para-
medics) likely to see patients experiencing anaphylaxis, 
should also be trained.
Limitations
A limitation of the present data is that the anaphylaxis 
registry contains only data submitted by allergy centers 
and/or allergology private practices. Since not all 
 patients attend for specialist treatment after suffering a 
severe allergic reaction, this is a source of bias. For 
example, a different distribution of triggers was found 
in the primary data collection from emergency 
 physicians (the most frequent possible triggers in the 
dataset from the emergency physicians was food, for 
both children and adults) (10).
Another analysis carried out among physicians in 
private practice has shown that the relative frequencies 
of triggers are to a significant extent determined by the 
specialty of the reporting physician (for example, che-
motherapeutic drugs in reports from oncologists) (26).
Although a large number of the allergy centers are 
active in the anaphylaxis registry, not all severe allergic 
reactions seen in allergy centers in Germany are re-
flected by the presented data. Nevertheless, because of 
the large number of participating centers in the registry, 
a sentinel role may be assumed.
Summary
We hope that the data in the anaphylaxis registry, to-
gether with collaboration between the various medical 
societies and other specialist medical associations, and 
the establishment of standardized patient training, will 
enable the situation regarding the care of anaphylaxis 
patients with severe allergic reactions in Germany to be 
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improved. This is necessary not least because what it is 
about is the most severe—potentially fatal—manifes-
tation of a mast-cell-dependent reaction.
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eBOX 1
Methods
Data collection by the anaphylaxis registry in the German-speaking countries (Germany, Austria, Switzerland) began in 2006. 
Participating centers enter the data on their anaphylaxis patients in a password-protected questionnaire in a pseudonymized 
and standardized manner. The data collected include details of trigger and circumstances accompanying the anaphylactic 
 reactions, together with information about the emergency treatment provided. Patients who have cardiovascular and/or respira-
tory symptoms in the course of an anaphylactic reaction are included. Data from patients who have only skin reactions, and 
 reported data from patients whose anaphylactic episode occurred more than a year before they first attended the reporting 
center, are not included in the analysis.
The ethical commission and data protection officer of the Berlin Charité Hospital approved the study (EA1/079/06). 
For the data collection from the Berlin emergency physicians, a shortened, one-page questionnaire generated by the 
 anaphylaxis registry was used. The data collected include: 
● Patient sex
● Patient age
● Symptoms
● Location where the reaction occurred
● Outcome of the reaction
● Triggering factors
● Emergency measures carried out. 
The detailed demographic and clinical data from this project have already been published, and for the purposes of the present 
study were referred to for comparative purposes exclusively for the period from 2010 to 2011 (10). This relates to 120 out of a 
total of 375 reported cases. At the beginning of the project, the emergency physicians were informed of the aim and data col-
lection parameters of the project. During the project, the data recorded were communicated to the emergency physicians in a 
newsletter at quarterly intervals.
In addition to the survey of emergency physicians in the Berlin area, we also carried out a retrospective analysis of the digitally 
documented emergency physician calls of the ADAC air rescue service with the key word “Anaphylaxie” (anaphylaxis) (2010 to 
2011, n = 994) in the whole of Germany. This analysis included the documentation of every callout of the ADAC air rescue 
 service in the indicated area archived under the emergency service diagnosis „anaphylaxis.“ Patient demographic data, the 
standard information on signs of alertness, data on the patient’s respiratory and cardiovascular status, and details of treatment 
 given were analyzed.
Statistical analysis 
Data management and descriptive analysis were carried out using SPSS for Windows version 19.0 and multinomial logistic 
 regression analysis using STATA version 11.
For continual data (e.g., age), mean ± SD, median, and range were calculated. For category variables, absolute and relative 
frequencies were calculated. The data are purely descriptive. No other statistical analysis was carried out.
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eBOX 2
We are grateful to all participating centers for their active collaboration:
● Germany:
 Aachen University Hospital, Dermatology; Aachen University Hospital, Pediatrics; Vital Klinik Alzenau, Dermatology, Dermatology Clinic, Charité 
 Allergy Center, Berlin; Berlin Spandau Hospital, Dermatology and Allergology; Pediatric Allergology, DRK Hospitals Berlin Westend; Ruhr-University 
Bochum, Dermatology; Ruhr-University Bochum, Pediatrics; St.-Marien-Hospital, Bonn, Adolescent Medicine; Protestant Hospitals in Bonn, Ear Nose 
and Throat Department; Bonn University Hospital, Dermatology; Bonn University Hospital, Pediatrics; Elbe Hospital Buxtehude, Dermatology Center; 
Dresden University Hospital, Adolescent Medicine; Dresden University Hospital, Dermatology; City Hospital, Dresden-Neustadt, Adolescent Medicine; 
Düsseldorf Protestant Hospital, Pediatric Cardiology, Adolescent Medicine; Barnim Hospital Eberswalde, Pediatric and Adolescent Medicine; 
 Erlangen University Hospital, Dermatology; Essen University Hospital, Dermatology; Freiburg University, Adolescent Medicine; Fürth Hospital, 
 Pediatric and Adolescent Medicine; University of Göttingen; University of Greifswald, Adolescent Medicine; University of Halle–Wittenberg, 
 Dermatology; Wilhelmstift Catholic Children’s Hospital, Hamburg, Pediatric Dermatology; Hamburg University Hospital, Dermatology; Hannover 
 Medical University, Dermatology; Hannover Medical University, Adolescent Medicine; University of Heidelberg, Dermatology; Heidelberg University 
Hospital, Pediatrics III; Saarland University Hospital at Homburg, Dermatology; University of Jena, Internal Medicine I; Schleswig-Holstein University 
Hospital, Kiel Campus, Dermatology; Schleswig-Holstein University Hospital, Lübeck Campus, Dermatology, Center for Pneumology; Schleswig-
 Holstein University Hospital, Lübeck Campus, Adolescent Medicine; Cologne University Hospital, Dermatology; Cologne University Hospital, 
 Adolescent Medicine; Leipzig University Hospital, Pediatric Pneumology and Allergology, Pediatric and Adolescent Medicine; Leipzig University 
 Hospital, Dermatology; University of Munich, Dermatology; Technical University of Munich, Dermatology; Friedrich Ebert Hospital, Neumünster, 
 Adolescent Medicine; Oldenburg Hospital, Pediatric and Adolescent Medicine; Osnabrück Christian Children’s Hospital, Pediatric and Adolescent 
 Medicine, Pneumology, Allergology; Kinderklinik III. Orden, Allergology and Pediatric Pneumology, Passau; St. Matthew’s Hospital, Rheine, Pediatric 
and Adolescent Medicine; Pediatric and Adolescent Medical Hospital, Rüsselsheim; Kloster Grafschaft Hospital, Schmallenberg; Asklepios Hospital 
Uckermark, Schwedt, Dermatology; St. John’s Hospital Treuenbritzen, Pneumology; Niederberg Hospital, Velbert, Pediatric and Adolescent Medicine; 
Wangen Hospital, Allgäu, Pediatric and Adolescent Medicine; Wiesbaden University Hospital, Rhinology; allergologists in practice in Aachen, 
 Hamburg, Stade, Würzburg.
● Austria:
Graz University Hospital, Dermatology; Graz University Hospital, Adolescent Medicine; Innsbruck Medical University, Dermatology; Salzburg Private 
University, Dermatology; Vienna Allergy and Clinical Immunology Outpatients Department; Vienna Medical University, Dermatology; Vienna Medical 
University, Pediatric and Adolescent Medicine.
● Switzerland:
Aarau Children’s Hospital, Pediatric Allergology and Pneumology; Basel University Hospital, Allergology Polyclinic; Lucerne Children’s Hospital, 
 Allergology Polyclinic, Pediatrics, Pediatric Allergology and Pneumology; University of Zurich Children’s Hospital; Zurich University Hospital, 
 Dermatology; Triemli Hospital, Zurich, Pediatrics.
